Department of Clinical Pharmacology, HCG Cancer Hospital, Bangalore, India
Research Article
Meropenem Versus Ceftazidime-Avibactam Versus Ceftazidime-Avibactam with Aztreonam as Empiric, First-Line Treatment of High-Risk Febrile Neutropenia: First Report of the CAMerA Trial, an Open-Labelled, Randomized-Controlled Trial
Author(s): Sachin Suresh Jadhav*, Jyothi Goutham Kumar, Anjali Matani, Amey C Panchal, Nishit Ojha, Sonu Tony and Yesheswini N Naik
Introduction: Infections due to Extended Spectrum Beta-Lactam (ESBL) positive, Carbapenemase Producing Enterobacteriaceae (CPE) and NDM1 resistance Enterobacteriaceae have significantly increased internationally and may account for up to 70% of infections in some geographies. Parallelly, high colistin resistance rates have also been reported. We are reporting the initial results of the first randomized-controlled trial addressing this issue of antibiotic resistant Gram-Negative Bacteremia (GNB).
Objectives: The objective of the study was to assess the efficacy of first-line Ceftazidime–Avibactam with or without Aztreonam in high-risk FN, versus Meropenem.
Methodology: Adult patients with high-risk FN were randomized to Meropenem, Ceftazidime-Avibactum or Ceftazidime-Avibactum with Aztreonam as the fi.. View More»
DOI:
10.35248/jcma.24.8.179